Detailed financial statements for OS Therapies Incorporated (OSTX): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $1.75, OSTX has negative trailing earnings (P/E not meaningful) and an ROE of 6.83%. Market capitalisation stands at $80M.
Balance sheet quality for OSTX: current ratio of 0.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $4250 | $1.2M | $805 | $4220 | $2780 | $363085 |
| Gross Profit | -$4250 | -$1.2M | -$805 | -$4220 | -$2780 | -$363085 |
| Research & Development | $602 | $2.2M | $3.3M | $3.2M | $2.8M | $16.36B |
| Selling, General & Admin | $795 | $1.5M | $1.2M | $1.1M | $4.0M | $12.34B |
| Operating Expenses | $1397 | $3.7M | $4.4M | $4.3M | $6.8M | $28.3M |
| Operating Income | -$5647 | -$4.8M | -$4.4M | -$4.3M | -$6.8M | -$28.7M |
| EBITDA | $61353 | -$4.8M | -$4.4M | -$4.3M | -$6.8M | -$28.4M |
| Interest Expense | $461.8M | $2.6M | $1.8M | $3.4M | $2.1M | 0 |
| Pre-tax Income | -$6027 | -$7.4M | -$6.3M | -$7.8M | -$8.9M | -$28.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$6027 | -$7.4M | -$6.3M | -$7.8M | -$8.9M | -$28.8M |
| EPS | $-0.00 | $-0.33 | $-0.28 | $-0.39 | $-0.52 | $-0.98 |
| EPS (Diluted) | $-0.00 | $-0.33 | $-0.28 | $-0.39 | $-0.52 | $-0.98 |
| Shares Outstanding (Diluted) | $8.4M | $23.1M | $23.1M | $20.0M | $20.9M | $29.3M |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.23B | $80788 | $171480 | $38982 | $5.5M | $269830 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $430.5M | $231071 | $1145 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.68B | $312815 | $496835 | $790032 | $5.5M | $332912 |
| Property, Plant & Equipment | $1.9M | $13076 | $12270 | $8050 | $5270 | $2490 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | $6.5M |
| Total Assets | $1.68B | $325891 | $509105 | $798082 | $5.5M | $6.8M |
| Accounts Payable | $40000 | $856521 | $1.2M | $2.7M | $1.7M | $9.9M |
| Short-term Debt | $871.2M | 0 | 0 | $14.6M | 0 | 0 |
| Total Current Liabilities | $2.10B | $3.5M | $6.1M | $24.7M | $4.6M | $11.8M |
| Long-term Debt | $5.90B | $7.1M | $10.3M | 0 | 0 | 0 |
| Total Liabilities | $8.00B | $11.8M | $18.1M | $24.8M | $4.7M | $12.9M |
| Retained Earnings | -$6.34B | -$15.2M | -$21.6M | -$29.5M | -$40.4M | -$67.2M |
| Total Equity | -$6.33B | -$11.5M | -$17.6M | -$24.0M | $811487 | -$6.1M |
| Total Debt | $6.77B | $7.1M | $10.3M | $14.6M | 0 | 0 |
| Net Debt | $5.54B | $7.0M | $10.2M | $14.6M | -$5.5M | -$269830 |
| Working Capital | -$427.1M | -$3.2M | -$5.7M | -$23.9M | $906217 | -$11.4M |
Cash Flow (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Income | -$6.03B | -$7.4M | -$6.3M | -$7.8M | -$8.9M | -$28.75B |
| Depreciation & Amortization | $67000 | $805 | $805 | $4220 | $2780 | $363.1M |
| Stock-based Compensation | 0 | 0 | 0 | 0 | $268300 | $4.27B |
| Change in Working Capital | $964.4M | $574668 | $947330 | $2.0M | -$129639 | $9.1M |
| Operating Cash Flow | -$2.41B | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.24B |
| Capital Expenditure | -$2.0M | -$11934 | 0 | 0 | 0 | -$466423 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | -$31.2M | 0 |
| Free Cash Flow | -$2.42B | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.24B |
Growth & Margins (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Income Growth (YoY) | -123016.8% | +15.7% | -24.6% | -14.0% | -223.7% | |
| EPS Growth (YoY) | -47042.9% | +15.2% | -39.3% | -33.3% | -88.5% | |
| Shares Change (YoY) | +174.3% | +0.0% | -13.2% | +4.1% | +40.2% | |
| FCF Growth (YoY) | +99.8% | +14.1% | +20.7% | -142.2% | -195423.2% | |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| FCF Per Share | $-286.76 | $-0.19 | $-0.16 | $-0.15 | $-0.35 | $-486.74 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $1.50 | $0.00 |
| Shares Outstanding (Basic) | $8.4M | $23.1M | $23.1M | $20.0M | $20.9M | $29.3M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | 683.03% |
| Return on Invested Capital | 350.07% |
| Return on Assets | -397.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 0.18 |
Key Ratios (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| P/E | -3585.71 | -7.61 | -8.96 | -6.44 | -8.23 | -1.43 |
| P/B | -0.00 | -5.06 | -3.30 | -2.10 | 110.07 | -6.72 |
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: ADAG · COEP · CRVO · EQ · HOWL · INKT · IOBT
Explore sector: Healthcare · Biotechnology
More sections of OSTX: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks